id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_ksthdbpq7vbwdm3jhrt2dav524	Jordan M. Schmitt	Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe	2012	4	.pdf	application/pdf	2835	271	59	In our study, we found that sunitinib + paclitaxel in patients with advanced esophageal or gastroesophageal junction cancer had a 24-week PFS no better than the PFS Despite advances in staging and treatment for patients with esophageal cancer, the relative 5-year survival rate for all advanced esophageal cancer7 and studies in patients with the study, patients, including those who discontinued protocol therapy early, were evaluated 30 days after the last phase II studies of patients with advanced esophageal cancer.9,10 Journal of Thoracic Oncology • Volume 7, Number 4, April 2012 Sunitinib Plus Paclitaxel in Esophageal Cancer Patients Journal of Thoracic Oncology • Volume 7, Number 4, April 2012 Sunitinib Plus Paclitaxel in Esophageal Cancer Patients Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Group Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Group	./cache/work_ksthdbpq7vbwdm3jhrt2dav524.pdf	./txt/work_ksthdbpq7vbwdm3jhrt2dav524.txt